Key takeaways for Wisconsin
- • Wegovy is the FIRST weight-loss GLP-1 with an MACE-reduction indication (Mar 2024).
- • Ozempic carries a CV indication in T2D adults with established CVD.
- • SELECT showed 20% MACE reduction over roughly 3.3 years on Wegovy.
- • BadgerCare Plus / Wisconsin Medicaid coverage rules apply for Cardiovascular Risk Reduction patients in Wisconsin — see Medicaid section below.
- • 16 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Cardiovascular Risk Reduction
Multiple GLP-1 drugs have FDA-approved cardiovascular indications. In March 2024, Wegovy became the first weight-loss drug approved to reduce risk of major adverse cardiovascular events (MACE) — cardiovascular death, non-fatal MI, non-fatal stroke — in adults with established CVD and obesity/overweight. Ozempic carries an MACE-reduction indication in T2D adults with established CVD. Evidence grade: A (large outcomes trials). Trulicity (dulaglutide) has a similar T2D CV indication via REWIND. These indications are based on dedicated CV outcomes trials, not extrapolation.
Wisconsin-specific context
Wisconsin has telehealth access concentrated in Milwaukee, Madison, Green Bay metros, with additional reach to Kenosha and Racine. UW Health, Aurora Health Care, Froedtert Health is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at www.dhs.wisconsin.gov.
Wisconsintelehealth & pricing rules
- • Wisconsin permits audio-only and asynchronous telehealth visits for GLP-1 care.
- • Wisconsin allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in Wisconsin: (compounded options often lower, brand higher).